<DOC>
	<DOCNO>NCT00002985</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether doxorubicin effective daunorubicin AIDS-related Kaposi 's sarcoma . PURPOSE : Randomized double-blinded phase III trial determine doxorubicin effective daunorubicin treat patient AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>Doxorubicin Treating Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical benefit doxorubicin HCl liposome ( Doxil ) compare baseline status treatment AIDS-related Kaposi 's sarcoma . II . Determine tumor response Doxil corollary clinical benefit . III . Evaluate safety Doxil . OUTLINE : This randomize , prospective , double blind , multicenter study . Patients randomly assign receive doxorubicin HCl liposome ( Doxil ) daunorubicin ( DaunoXome ) 3:1 ratio . Both Doxil DauonoXome give every 2 week 6 course intravenous infusion 60 minute peripheral vein . PROJECTED ACCRUAL : 80 patient study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : AIDSrelated Kaposi 's sarcoma require systemic chemotherapy One following ( Kaposi 's sarcoma AIDSassociated ) : Edema impair functional activity Symptomatic , evaluable pulmonary Kaposi 's sarcoma document within 3 month study Symptomatic , evaluable GI Kaposi 's sarcoma document within 3 month study Moderate severe pain despite use analgesic Lesion ( ) patient feel disfigure impair patient 's selfimage daily activity At least 5 bidimensionally measurable monocutaneous lesion PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 40100 % Life expectancy : At least 120 day Hematopoietic : Neutrophil count least 1,200 cells/mm3 Platelet count least 75,000 cells/mm3 Hemoglobin least 9.0 g/dL Hepatic : Creatinine le 2 time upper limit normal ( ULN ) Bilirubin le 2 time ULN Renal : Not specify Cardiovascular : Cardiac ejection fraction least 50 % No histopathological evidence antracyclineinduced cardiomyopathy Pulmonary : No significant nonKaposi 's sarcoma associate pulmonary insufficiency ( define oxygen saturation le 90 % ) Other : Not pregnant nursing Fertile woman must use medically prove method birth control No opportunistic infection past 4 week No active malignancy except basal squamous cell carcinoma skin situ cervical anal carcinoma No neuropsychiatric history alter mental status prevents inform consent compliance protocol requirement PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 14 day since prior antiKaposi 's sarcoma therapy No prior Doxil DaunoXome No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiation therapy Surgery : Not specify Other : Antiviral therapy allow Colony stimulate factor allow Erythropoietin allow Prophylactic therapy , maintenance therapy treatment HIVassociated opportunistic infection allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
</DOC>